FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166557024> ?p ?o ?g. }

• W3166557024 endingPage "e21202" @default.
• W3166557024 startingPage "e21202" @default.
• W3166557024 abstract "e21202 Background: Increased systemic inflammatory state and increased inflammation within tumor micro-environment (TME) have been associated with a worse prognosis and lower responsiveness to immune checkpoint inhibitors (ICI). Systemic inflammatory immune index (SII) reflects the changes in the systemic inflammatory matrix. Studies have shown the association of SII with cancer survival and treatment outcomes. We aim to study the effect of SII on treatment outcomes in non-small cell lung cancer (NSCLC) patients being treated with ICI. Methods: We conducted a retrospective analysis on 178 NSCLC patients treated with ICIs (pembrolizumab, nivolumab, ipilimumab/nivolumab or atezolizumab) alone or in combination with chemotherapy. SII is the product of platelets multiplied by neutrophils divided by lymphocytes. Baseline and 8-week SIIs were obtained. Radiographic response, duration of radiographic response (date of best response to radiographic progression), overall survival (OS), and progression-free survival (PFS) were evaluated. A high SII was defined as a value greater than the median SII. Cox regression univariate and multivariate analyses were performed. Logistic regression, t-test, and Chi-square tests were applied. Results: Overall, 81% patients had adenocarcinoma and 19% patients had squamous, adenosquamous or large cell carcinoma. The majority of the patients were female (56.2% vs. 43.8%). Median SII at baseline was 1335. The objective response rate (ORR) was 45.1%. The disease control rate was 75.8%. The ORR was 51% in patients receiving ICI first-line compared to 35% in those who received ICI as a second-line therapy. At baseline, there was no difference in the mean SII between responders and non-responders (2146.2 vs. 1917.5, P = 0.5); however at 8 weeks, the mean SII was significantly lower in responders compared to non-responders (1198.8 vs. 2880.2, P = 0.02). A total of 15 (10.9%) patients were found to have pseudoprogression or mixed response on follow-up imaging. Among these, 11(73.3%) patients had low SII at 8 weeks (P = 0.04). The median OS was significantly higher in patients with low SII at baseline (29.6 months vs. 10.1 months, P = 0.001 95% CI 10.6 – 22.1). Similarly, there was a significant difference in median PFS in patients with low SII (14.6 months vs. 6.7 months, P = 0.002, 95% CI 5.6 – 11.6). There was no correlation between high or low SII on the incidence of immune-related adverse events. Conclusions: SII may have significant impact on OS and PFS and could be serially monitored to assess the response to ICI. A low SII may help to differentiate pseudoprogression vs. true progression. Prospective studies are needed to validate these findings. Further, it will be interesting to see if SII could be incorporated into predictive models to determine the duration of cytotoxic therapy in selected patients." @default.
• W3166557024 created "2021-06-22" @default.
• W3166557024 creator A5044045808 @default.
• W3166557024 creator A5065299099 @default.
• W3166557024 creator A5065795041 @default.
• W3166557024 creator A5067865502 @default.
• W3166557024 creator A5074714454 @default.
• W3166557024 creator A5082877808 @default.
• W3166557024 date "2021-05-20" @default.
• W3166557024 modified "2023-10-13" @default.
• W3166557024 title "Baseline systemic inflammatory immune index may predict overall survival and progression-free survival in patients with non-small cell lung cancer patients on immune checkpoint inhibitors." @default.
• W3166557024 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21202" @default.
• W3166557024 hasPublicationYear "2021" @default.
• W3166557024 type Work @default.
• W3166557024 sameAs 3166557024 @default.
• W3166557024 citedByCount "2" @default.
• W3166557024 countsByYear W31665570242022 @default.
• W3166557024 crossrefType "journal-article" @default.
• W3166557024 hasAuthorship W3166557024A5044045808 @default.
• W3166557024 hasAuthorship W3166557024A5065299099 @default.
• W3166557024 hasAuthorship W3166557024A5065795041 @default.
• W3166557024 hasAuthorship W3166557024A5067865502 @default.
• W3166557024 hasAuthorship W3166557024A5074714454 @default.
• W3166557024 hasAuthorship W3166557024A5082877808 @default.
• W3166557024 hasConcept C121608353 @default.
• W3166557024 hasConcept C126322002 @default.
• W3166557024 hasConcept C143998085 @default.
• W3166557024 hasConcept C2776256026 @default.
• W3166557024 hasConcept C2776694085 @default.
• W3166557024 hasConcept C2777701055 @default.
• W3166557024 hasConcept C2780030458 @default.
• W3166557024 hasConcept C2780057760 @default.
• W3166557024 hasConcept C2780739268 @default.
• W3166557024 hasConcept C2781433595 @default.
• W3166557024 hasConcept C67761136 @default.
• W3166557024 hasConcept C71924100 @default.
• W3166557024 hasConceptScore W3166557024C121608353 @default.
• W3166557024 hasConceptScore W3166557024C126322002 @default.
• W3166557024 hasConceptScore W3166557024C143998085 @default.
• W3166557024 hasConceptScore W3166557024C2776256026 @default.
• W3166557024 hasConceptScore W3166557024C2776694085 @default.
• W3166557024 hasConceptScore W3166557024C2777701055 @default.
• W3166557024 hasConceptScore W3166557024C2780030458 @default.
• W3166557024 hasConceptScore W3166557024C2780057760 @default.
• W3166557024 hasConceptScore W3166557024C2780739268 @default.
• W3166557024 hasConceptScore W3166557024C2781433595 @default.
• W3166557024 hasConceptScore W3166557024C67761136 @default.
• W3166557024 hasConceptScore W3166557024C71924100 @default.
• W3166557024 hasIssue "15_suppl" @default.
• W3166557024 hasLocation W31665570241 @default.
• W3166557024 hasOpenAccess W3166557024 @default.
• W3166557024 hasPrimaryLocation W31665570241 @default.
• W3166557024 hasRelatedWork W2155654588 @default.
• W3166557024 hasRelatedWork W3028730736 @default.
• W3166557024 hasRelatedWork W3094969222 @default.
• W3166557024 hasRelatedWork W3136608335 @default.
• W3166557024 hasRelatedWork W3166557024 @default.
• W3166557024 hasRelatedWork W3206418811 @default.
• W3166557024 hasRelatedWork W3215044659 @default.
• W3166557024 hasRelatedWork W3216520672 @default.
• W3166557024 hasRelatedWork W4292999071 @default.
• W3166557024 hasRelatedWork W4308384320 @default.
• W3166557024 hasVolume "39" @default.
• W3166557024 isParatext "false" @default.
• W3166557024 isRetracted "false" @default.
• W3166557024 magId "3166557024" @default.
• W3166557024 workType "article" @default.